Form D · Other Technology
Beacon Biosignals, Inc.
Boston, MA · CIK 0001765647
Offering snapshot reported Apr 15, 2026 · SEC filing
- Reported sold
- $103M Offering amount: $103M
- Investors reported
- 43 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 7, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 15, 2026 | Initial | $103,280,711 | No comparison | 43 | SEC filing |
| Oct 4, 2021 | Initial | $29,850,019 | No comparison | 42 | SEC filing |
| Feb 7, 2019 | Initial | $50,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-580615
Source: Form D, filed Apr 15, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jacob A. Donoghue | Director, Executive |
| Jacob A. Donoghue, M.D., Ph.D. | Director, Executive |
| Caitlin Donovan | Director |
| Pavel Raifeld | Director |
| Naveen Rao | Director |
| Jarrett Revels | Executive |
Issuer details
Industry: Other Technology (See others in industry)
Address:
22 Boston Wharf Road Floor 7
Boston, MA, 02210
Boston, MA, 02210